Myeloma Awareness Month: Patients are Living Longer Thanks to New Treatments

Thanks to the development of new treatments, people with multiple myeloma are living longer lives. Recently, researchers gathered to begin defining what a “cure” is for myeloma. This is because patients are living for many years after their diagnosis. 

Understanding the change in myeloma prognosis over time shows how important clinical research is for people living with rare diseases like multiple myeloma. Researchers are still learning what affects survival in multiple myeloma, how new therapies have shaped the treatment landscape, and how to improve patient quality of life over time.

Myeloma patients live longer in the era of personalized-precision medicine 

The transformation in how long people live with multiple myeloma is one of the most significant success stories in modern cancer care. 

In the 1990s and early 2000s, a myeloma diagnosis often came with a very guarded outlook. Most patients lived for an average of only 3 to 5 years using standard chemotherapy. 

That changed with the introduction of new therapies. Proteasome inhibitors, immunomodulatory drugs, and stem cell transplants began to change this timeline rapidly. By the mid-2010s, the average survival time had nearly doubled. Today, many people live 10 to 20 plus years after their myeloma diagnosis. 

Data from 2024 and 2025 show that the newest "quadruplet" treatments (using four drugs together) and advanced options like CAR-T cell therapy are pushing these boundaries even further. Because of these advances, myeloma is increasingly managed as a chronic, long-term condition rather than an acute illness, allowing people to focus more on their overall quality of life and long-term wellness.

To learn our history is to watch our progress

Progress means that while myeloma continues to be diagnosed, patients' life expectancy has expanded dramatically. This has given patients access to years of life that were not possible just a generation ago.

A large study investigated the causes of death in people who received auto-SCT and people who didn’t

An ASH study completed in 2022 analyzed 6,677 patients with multiple myeloma and compared people who received an autologous stem cell transplant (auto-SCT) with those who didn’t. The analysis showed:

• Myeloma was the main cause of mortality (about 74% in transplant patients and 67% in non-transplant patients)
• Median survival was longer in transplant patients (8.4 years vs. 3.0 years)
• Newer therapies were linked to improved survival and fewer myeloma-related deaths

Which myeloma risk factors were important to look out for? 

The most important study takeaway is that controlling the myeloma itself remains the most important goal to extend survival. It also noted some risk factors that were more common in people who passed due to myeloma itself. For example, CRAB features (high calcium, kidney problems, anemia, bone disease) posed a higher risk of complications that increased mortality.

What other non-myeloma risk factors are relevant in myeloma mortality? 

Having another type of cancer was the second most common cause, indicating the importance of regular screening to detect colon, skin, prostate, or breast cancer. Depending on your health history, your doctor will indicate what to prioritize on each visit.

Less frequently, the findings also noted that having heart disease and infections also contributed to mortality. 

Heart disease should be monitored and treated by a cardiologist, which is a doctor specialized in heart disorders. Lifestyle changes such as exercise and a nutrient rich diet can also improve heart health. 

Infections are common among myeloma patients due to two factors: 

• The therapies used to treat the myeloma
• The myeloma itself that can impact the production of white blood cells 

Preventing infections is very important. Tell your doctor right away if you have even a mild fever, chills, or flu-like symptoms. Even small infections can be dangerous when you have a weakened immune system. 

New strategies of infection prevention are now being explored, for instance, remote monitoring of symptoms have reduced the infection-related hospitalizations. 

If myeloma continues to be the main cause of death, why has the mortality rate significantly reduced in the last 20 years? 

Myeloma-related deaths have decreased over time, especially with the use of newer therapies. This can be attributed to using more sensitive methods to detect myeloma cells, such as minimal residual disease (MRD). 

Other factors, like patient participation in clinical trials, self-advocacy, and patient education material like HealthTree University have also improved patient literacy regarding their own health and control over the treatment course. Having an online community and being able to reach out to more people have given people a landscape that was harder to achieve 20 years ago: hope for more options. 

As patients live longer, understanding non-myeloma causes of death becomes more important. Personalized medicine is also becoming one of the main focus points of research. 

Become a part of the HealthTree community, where we provide tools to keep track of your health, participate in patient-centered clinical trials, understand your disease, and connect with other myeloma patients and advocates, all in one place. 

CREATE YOUR FREE ACCOUNT 

Why is it important to understand the causes of death in myeloma?

Talking about death causes can feel overwhelming, but these findings also highlight progress. Knowing what drives outcomes in myeloma can help guide care decisions. Learning this can help patients and doctors prioritize treatment and monitoring goals. It also helps patients understand that living longer with myeloma means paying attention to more than just the cancer.

What does the future hold for myeloma mortality?

Looking ahead, the future of myeloma care is defined by a continued and steady decline in mortality. According to recent long-term forecasting models published in Blood (2025), we are entering an era in which survival gaps are narrowing across all patient groups, regardless of age or background. 

As we move toward 2040, researchers expect that the shift from "treating a crisis" to "managing a chronic condition" will become the standard of care. This progress is driven by the early use of highly effective immunotherapies and a deeper understanding of how to prevent complications before they start. While the journey continues, the data suggests that for many, a myeloma diagnosis will no longer be defined by its limitations, but by the decades of life made possible through science and proactive health management.

Working closely with your care team to monitor your disease, prevent complications, and support your well-being is one of the most powerful steps you can take.

Don’t miss the latest myeloma news and community events. Subscribe to our weekly Myeloma Newsletter.

SUBSCRIBE TO NEWSLETTER

Source: 

• Causes of Death Among Patients with Multiple Myeloma: A 10 Year Longitudinal Analysis of a Population-Based Cohort in Ontario, Canada
• A historical perspective on milestones in multiple myeloma research
• Long-term projections of multiple myeloma mortality in the United States(2024-2040).: A time-series analysis stratified by sex, race, and geography